The potential role of dexmedetomidine on neuroprotection and its possible mechanisms: Evidence from in vitro and in vivo studies

Kantarakorn Unchiti,Prangmalee Leurcharusmee,Artid Samerchua,Tanyong Pipanmekaporn,Nipon Chattipakorn,Siriporn C. Chattipakorn
DOI: https://doi.org/10.1111/ejn.15474
IF: 3.698
2021-10-25
European Journal of Neuroscience
Abstract:Neurological disorders following brain injuries and neurodegeneration are on the rise worldwide, and cause disability and suffering in patients. It is crucial to explore novel neuroprotectants. Dexmedetomidine, a selective α2-adrenoceptor agonist, is commonly used for anxiolysis, sedation, and analgesia in clinical anesthesia and critical care. Recent studies have shown that dexmedetomidine exerts protective effects on multiple organs. This review summarized and discussed the current neuroprotective effects of dexmedetomidine, as well as the underlying mechanisms. In preclinical studies, dexmedetomidine reduced neuronal injury and improved functional outcomes in several models, including hypoxia-induced neuronal injury, ischemic-reperfusion injury, intracerebral hemorrhage, post-traumatic brain injury, anesthetic-induced neuronal injury, substance-induced neuronal injury, neuroinflammation, epilepsy, and neurodegeneration. Several mechanisms are associated with the neuroprotective function of dexmedetomidine, including neurotransmitter regulation, inflammatory response, oxidative stress, apoptotic pathway, autophagy, mitochondrial function, and other cell signaling pathways. In summary, dexmedetomidine has the potential to be a novel neuroprotective agent for a wide range of neurological disorders.
neurosciences
What problem does this paper attempt to address?